Systemic AA amyloidosis

Subcellular Biochemistry

Volumn 65, Issue , 2012, Pages 541-564

  Pinney, Jennifer H ^a   Lachmann, Helen J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Dialysis; End stage renal failure; Immunosuppression; Inflammation; Nephrotic syndrome; Proteinuria; SAP scintigraphy; Transplantation

Indexed keywords

SERUM AMYLOID A;

AMYLOIDOSIS; ANIMAL; BLOOD; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; DISEASE FREE SURVIVAL; HUMAN; INFLAMMATION; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGIC MONITORING; PROTEINURIA; REVIEW; SURVIVAL RATE;

AMYLOIDOSIS; ANIMALS; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MONITORING, PHYSIOLOGIC; PROTEINURIA; SERUM AMYLOID A PROTEIN; SURVIVAL RATE;

EID: 84894587290     PISSN: 03060225     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-5416-4_20     Document Type: Article

References (96)

1. Altiparmak MR, Pamuk ON, Ataman R, Serdengecti K (2004) Continuous ambulatory peritoneal dialysis in familial Mediterranean fever amyloidosis patients with end-stage renal failure: a single-centre experience from Turkey. Nephron Clin Pract 98:c119-c123
2. Aydinli B, Ozturk G, Balik AA, Aslan S, Erdogan F (2006) Spontaneous rupture of the spleen in secondary amyloidosis: a patient with rheumatoid arthritis. Amyloid 13:160-163
3. Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, SalvadoriM (2008) Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant 23:941-951
4. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468:93-97
5. Bollee G, Guery B, Joly D, Snanoudj R, Terrier B, Allouache M, Mercadal L, Peraldi MN, Viron B, Fumeron C, Elie C, Fakhouri F (2008) Presentation and outcome of patients with systemic amyloidosis undergoing dialysis. Clin J Am Soc Nephrol 3:375-381
6. Booth DR, Booth SE, Gillmore JD, Hawkins PN, Pepys MB (1998) SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 5:262-265
7. Botto M, Hawkins PN, Bickerstaff MCM, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA,Walport MJ, PepysMB (1997)Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nature Med 3:855-859
8. Brater DC (1998) Diuretic therapy. N Engl J Med 339:387-395
9. Dember LM, Hawkins PN, Hazenberg BPC, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puechal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M (2007) Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 356:2349-2360
10. Dispenzieri A, Gertz M, Kyle R, Lacy M, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751-3757
11. Dubrey SW, Cha K, Simms RW, Skinner M, Falk RH (1996) Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol 77:313-315
12. Ebert EC, Nagar M (2008) Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol 103:776-787
13. Emeksiz H, Bakkaloglu S, Camurdan O, Boyraz M, Soylemezoglu O, Hasanoglu E, BuyanN (2010) Acute adrenal crisis mimicking familial Mediterranean fever attack in a renal transplant FMF patient with amyloid goiter. Rheumatol Int 30:1647-1649
14. Filipowicz-Sosnowska AM, Roztropowicz-Denisiewicz K, Rosenthal CJ, Baum J (1978) The amyloidosis of juvenile rheumatoid arthritis-comparative studies in Polish and American children. I. Levels of serum SAA protein. Arthritis Rheum 21:699-703
15. Fish R, Pinney J, Jain P, Addison C, Jones C, Jayawardene S, Booth J, Howie AJ, Ghonemy T, Rajabali S, Roberts D, White L, Khan S, Morgan M, Cockwell P, Hutchison CA (2010) The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol 5:1977-1980
16. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC (2010) Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 122:138-144
17. Fraser AG, Arthur JF, Hamilton I (1991) Intestinal pseudoobstruction secondary to amyloidosis responsive to cisapride. Dig Dis Sci 36:532-535
18. Gellermann GP, Appel TR, Tannert A, Radestock A, Hortschansky P, Schroeckh V, Leisner C, Lutkepohl T, Shtrasburg S, Rocken C, Pras M, Linke RP, Diekmann S, Fandrich M (2005) Raft lipids as common components of human extracellular amyloid fibrils. Proc Natl Acad Sci U SA 102:6297-6302
19. Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A (2003). The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 48:1149-1155
20. Gertz MA, Kyle RA, Greipp PR (1983) Hyposplenism in primary systemic amyloidosis. Ann Intern Med 98:475-477
21. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79:319-328
22. Gervais F, Chalifour R, Garceau D, Kong X, Laurin J, McLaughlin R, Morissette C, Paquette J (2001) Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 8(Suppl 1):28-35
23. Gervais F, Morissette C, Kong X (2003) Proteoglycans and amyloidogenic proteins in peripheral amyloidosis. Curr Med Chem Immunol Endocr Metab Agents 3:361-370
24. Gillmore JD, Booth DR, Madhoo S, Pepys MB, Hawkins PN (1999) Hereditary renal amyloidosis associated with variant lysozyme in a large English family. Nephrol Dial Transplant 14:2639- 2644
25. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN (2001) Amyloid load and clinical outcome inAA amyloidosis in relation to circulating concentration of serum amyloidA protein. Lancet 358:24-29
26. Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH, Li LS,Wechalekar A, Hawkins PN (2009) Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol 20:444-451
27. Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB (2010) Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 148:760-767
28. Goldfinger SE (1972) Colchicine for familial Mediterranean fever. N Engl J Med 287:1302
29. Gomez-Casanovas E, Sanmarti R, Sole M, Canete JD, Munoz-Gomez J (2001) The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 44:66-72
30. Hachulla E, Maulin L, Deveaux M, Facon T, Blétry O, Vanhille P, Wechsler B, Godeau P, Levesque H, Hatron PY, Huglo D, Devulder B, Marchandise X (1996) Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis. Am J Med 101:77-87
31. Hallen J, Madsen L, Ladefoged S, Fagerland MW, Serebruany VL, Agewall S, Atar D (2011) Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease. Scand J Urol Nephrol 45:151-158
32. Haq A, Hussain S, Meskat B, Mohan P, Conlon P, Hickey DP (2007) Complications of renal transplantation in patients with amyloidosis. Transplant Proc 39:120-124
33. Hawkins PN (2002) Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 11:649-655
34. Hawkins PN, Myers MJ, Lavender JP, Pepys MB (1988) Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet 1:1413-1418
35. Hawkins PN, Lavender JP, Pepys MB (1990) Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 323:508-513
36. Hazenberg BPC, Grond J,Van Den Top D, Bijzet J, Limburg PC, van RijswijkMH (1991) Immunohistochemical detection of amyloid AA in formaline-fixed paraffin-embedded rectal biopsies with the monoclonal anti-human SAA antibody Reu.86.2. In: Natvig JB, Forre O, Husby G, Husebekk A, Skogen B, Sletten K,Westermark P (eds) Amyloid and Amyloidosis 1990. Kluwer Academic, Dordrecht, pp 809-812
37. Hazenberg BP, van Rijswijk MH, Piers DA, Lub-de Hooge MN,Vellenga E, Haagsma EB, Hawkins PN, Jager PL (2006) Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 119:355.e15-355.e24
38. Hazenberg BP, Bijzet J, Limburg PC, Skinner M, Hawkins PN, Butrimiene I, Livneh A, Lesnyak O, Nasonov EL, Filipowicz-Sosnowska A, Gul A, Merlini G, Wiland P, Ozdogan H, Gorevic PD, Maiz HB, Benson MD, Direskeneli H, Kaarela K, Garceau D, HauckW, Van Rijswijk MH (2007) Diagnostic performance of amyloidA protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid 14:133-140
39. Herskovic T, Bartholomew LG, Green PA (1964) Amyloidosis and malaabsorption syundrome. Arch Intern Med 114:629-633
40. Hind CRK, Collins PM, Caspi D, Baltz ML, Pepys MB (1984) Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits. Lancet 2:376-378
41. Hrncic R,Wall J,Wolfenbarger DA, Murphy CL, Schell M,Weiss DT, SolomonA (2000) Antibodymediated resolution of light chain-associated amyloid deposits. Am J Pathol 157:1239-1246
42. JeongYS, Jun JB, KimTH, Lee IH, Bae SC,Yoo DH, Park MH, KimSY (2000) Successful treatment of protein-losing enteropathy due toAA amyloidosis with somatostatin analogue and high dose steroid in ankylosing spondylitis. Clin Exp Rheumatol 18:619-621
43. John B, Tan BK, Dainty S, Spanel P, Smith D, Davies SJ (2010) Plasma volume, albumin, and fluid status in peritoneal dialysis patients. Clin J Am Soc Nephrol 5:1463-1470
44. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, SzarekWA (1995) Arresting amyloidosis in vivo using small molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nature Med 1:143-148
45. Kofman T, Grimbert P, Canoui-Poitrine F, Zuber J, Garrigue V, Mousson C, Frimat L, Kamar N, Couvrat G, Bouvier N, Albano L, Le Thuaut A, Pillebout E, Choukroun G, Couzi L, Peltier J, Mariat C, Delahousse M, Buchler M, Le Pogamp P, Bridoux F, Pouteil-Noble C, Lang P, Audard V (2011) Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study. Am J Transplant 11:2423-2431
46. Koivuniemi R, Paimela L, Suomalainen R, Tornroth T, Leirisalo-Repo M (2008) Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 15:262-268
47. Korbet SM (2003) Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol 23:219-228
48. Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN (2007) Natural history and outcome in systemicAA amyloidosis. N Engl J Med 356:2361-2371
49. Lachmann HJ, Gillmore JD, Wechalekar AD, Sattianayagam PT, Gibbs SDJ, Pinney JH, Goodman HJB, Offer M, Gallimore JR, Gilbertson JA, Hunt T, Gopaul D, Hutt DF, Hawkins PN (2010). Survival on dialysis and outcome after renal transplantation inAAamyloidosis. Amyloid 17(Suppl 1):73
50. Lange U, Boss B, Teichmann J, Klor HU, Neeck G (2000) Serum amyloid A-an indicator of inflammation in ankylosing spondylitis. Rheumatol Int 19:119-122
51. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N (1998) Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 35:745-753
52. Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S, Vlodavsky I, Kisilevsky R, Lindahl U (2005) In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci U S A 102:6473-6477
53. Linke RP, Oos R,Wiegel NM, NathrathWB (2006) Classification of amyloidosis: misdiagnosing by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem 108:197-208
54. Lowrie EG, Lew NL (1990) Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482
55. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111:186-193
56. Magy-Bertrand N, Dupond JL,Mauny F, DupondAS, Duchene F, Gil H, KantelipB (2008) Incidence of amyloidosis over 3 years: the AMYPRO study. Clin Exp Rheumatol 26:1074-1078
57. Maulin L, Hachulla E, Deveaux M, Janin A,Wechsler B, Godeau P, Rousset H, Barrier JH, Hatron PY, Devulder B, Huglo D, Marchandise X (1997) 'Localized amyloidosis': 123I-labelled SAP component scintigraphy and labial salivary gland biopsy. Q J Med 90:45-50
58. Moriguchi M,Terai C,KosekiY, Uesato M, NakajimaA, Inada S, Nishinarita M, Uchida S, Nakajima A, Kim SY, Chen CL, Kamatani N (1999) Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet 105:360-366
59. Muller D, Roessner A, Rocken C (2000) Distribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and alpha 2-macroglobulin in cases of generalized AA- and AL amyloidosis. Virchows Arch 437:521-527
60. Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M (2006) Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford) 45:43-49
61. Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G (2009) Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 61:1435-1440
62. Odabas AR, Cetinkaya R, SelcukY, Bilen H (2001) Effect of losartan treatment on the proteinuria in normotensive patients having proteinuria due to secondary amyloidosis. Ups J Med Sci 106:183-188
63. O'Nuallain B, Wetzel R (2002) Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci U S A 99:1485-1490
64. Palladini G, Lavatelli F, Russo P, Perlini S, PerfettiV, Bosoni T, Obici L, Bradwell AR, D'Eril GM, Fogari R, Moratti R, Merlini G (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854-3858
65. Parmelee DC, Titani K, Ericsson LH, Eriksen N, Benditt EP,WalshKA (1982)Amino acid sequence of amyloid-related apoprotein (apoSAA1) from human high density lipoprotein. Biochemistry 21:3298-3303
66. Pepys MB, Butler PJG (1987) Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Biochem Biophys Res Commun 148:308-313
67. Pepys MB, Herbert J, HutchinsonWL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417:254-259
68. Perugini E, Rapezzi C, Piva T, Leone O, Bacchi-Reggiani L, Riva L, Salvi F, Lovato L, Branzi A, Fattori R (2006) Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 92:343-349
69. Potysova Z, Merta M, Tesar V, Jancova E, Honsova E, Rysava R (2009) Renal AA amyloidosis: survey of epidemiologic and laboratory data from one nephrology centre. Int Urol Nephrol 41:941-945
70. Puchtler H, Sweat F, Levine M (1962) On the binding of Congo red by amyloid. J Histochem Cytochem 10:355-364
71. Renzulli P, Schoepfer A, Mueller E, Candinas D (2009) Atraumatic splenic rupture in amyloidosis. Amyloid 16:47-53
72. Rocken C, Schwotzer EB, Linke RP, Saeger W (1996) The classification of amyloid deposits in clinicopathological practice. Histopathology 29:325-335
73. Rowczenio D, DoganA, Theis JD, Vrana JA, Lachmann HJ,WechalekarAD, Gilbertson JA, Hunt T, Gibbs SD, Sattianayagam PT, Pinney JH, Hawkins PN, Gillmore JD (2011) Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I.Am J Pathol 179:1978-1987
74. Ruggenenti P, Mosconi L, Vendramin G, Moriggi M, Remuzzi A, Sangalli F, Remuzzi G (2000) ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. Am J Kidney Dis 35:381-391
75. Saatci Ü, Ozen S, Özdemir S, Bakkaloglu A, Besbas N, Topaloglu R, Arslan S (1997) Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr 156:619-623
76. Sahin S, SahinGM,Ergin H, KantarciG (2007) The effect of dialytic modalities on clinical outcomes in ESRD patients with familial Mediterranean fever. Ren Fail 29:315-319
77. Shah PL, Gillmore JD, Copley SJ, Collins JV,WellsAU, du Bois RM, Hawkins PN, NicholsonAG (2002) The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. SarcoidosisVasc Diffuse Lung Dis 19:134-142
78. Sherif AM, Refaie AF, Sobh MA, Mohamed NA, Sheashaa HA, Ghoneim MA (2003) Long-term outcome of live donor kidney transplantation for renal amyloidosis.AmJ Kidney Dis 42:370-375
79. SnowAD, Kisilevsky R,Willmer J, Prusiner SB, DeArmond SJ (1989) Sulfated glycosaminoglycans in amyloid plaques of prion diseases. Acta Neuropathol 77:337-342
80. SolakY, Polat I,Atalay H,Turk S (2010) Whenurine is no longer beneficial: renal artery embolisation in severe nephrotic syndrome secondary to amyloidosis. Amyloid 17:24-36
81. Stix B, Kahne T, Sletten K, Raynes J, Roessner A, Rocken C (2001) Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3. Am J Pathol 159:561-570
82. Svantesson H,Akesson A, Eberhardt K, Elborgh R (1983) Prognosis in juvenile rheumatoid arthritis with systemic onset. A follow-up study. Scand J Rheumatol 12:139-144
83. Tabbibizar R, MaiselA (2002) The impact of B-type natriuretic peptide levels on the diagnoses and management of congestive heart failure. Curr Opin Cardiol 17:340-345
84. Tennent GA (1995) Structural and functional aspects of the pentraxins and SAA in the acute phase response and amyloidosis. Dissertation, University of London, 92:4299-4303
85. Touitou I, Sarkisian T, Medlej-Hashim M, Tunca M, Livneh A, Cattan D, Yalcinkaya F, Ozen S, Majeed H, Ozdogan H, Kastner D, Booth D, Ben-Chetrit E, Pugnere D, Michelon C, Seguret F, Gershoni-Baruch R (2007) Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 56:1706-1712
86. Turgut F, Kanbay M, KayaA, Uz B,AkcayA (2007) Bilateral renal artery embolization in a case with severe proteinuria secondary to amyloidosis in a hemodialysis patient. Amyloid 14:157-158
87. Ueno T, Takeda K, NagataM (2012) Remission of proteinuria and preservation of renal function in patients with renal AA amyloidosis secondary to rheumatoid arthritis. Nephrol Dial Transplant 27:633-639
88. Urieli-Shoval S, Linke RP, MatznerY (2000) Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7:64-69
89. Utku U, Dilek M,Akpolat I, BedirA,Akpolat T (2007) SAA1 alpha/alpha alleles in Behcet's disease related amyloidosis. Clin Rheumatol 26:927-929
90. van der Hilst JC,YamadaT, Op den Camp HJ, van der MeerJW, Drenth JP, SimonA(2008) Increased susceptibility of serum amyloidA1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology (Oxford) 47:1651-1654
91. von Hutten H, Mihatsch M, Lobeck H, Rudolph B, Eriksson M, Rocken C (2009) Prevalence and origin of amyloid in kidney biopsies. Am J Surg Pathol 33:1198-1205
92. Wu HM, Tang JL, Sha ZH, Cao L, LiYP (2004) Interventions for preventing infection in nephrotic syndrome. Cochrane Database Syst Rev CD003964
93. Yam LT, Oropilla SB (1991) Octreotide for diarrhea in amyloidosis. Ann Intern Med 115:577
94. Yamada T (1999) Serum amyloidA (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 37:381-388
95. Yamada T, OkudaY, Takasugi K, Itoh K, Igari J (2001) Relative serum amyloidA (SAA) values: the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 60:124-127
96. Yilmaz R, Ozer S, Ozyurt H, Erkorkmaz U, Sahin S (2009) Familial Mediterranean fever gene mutations in the inner northern region ofTurkey and genotype-phenotype correlation in children. J Paediatr Child Health 45:641-645